Natures Sunshine Products (NATR)
Market Price (7/15/2026): $20.49 | Market Cap: $359.0 MilSector: Consumer Staples | Industry: Packaged Foods & Meats
Natures Sunshine Products (NATR)
Market Price (7/15/2026): $20.49Market Cap: $359.0 MilSector: Consumer StaplesIndustry: Packaged Foods & Meats
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 5.5%, FCF Yield is 6.4% Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -18% Low stock price volatilityVol 12M is 48% Megatrend and thematic driversMegatrends include Health & Wellness Trends. Themes include Nutritional Supplements, and Organic & Natural Products. | Weak multi-year price returns3Y Excs Rtn is -21% | Key risksNATR key risks include [1] extensive regulatory and compliance hurdles specific to its international direct selling business model, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 5.5%, FCF Yield is 6.4% |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -18% |
| Low stock price volatilityVol 12M is 48% |
| Megatrend and thematic driversMegatrends include Health & Wellness Trends. Themes include Nutritional Supplements, and Organic & Natural Products. |
| Weak multi-year price returns3Y Excs Rtn is -21% |
| Key risksNATR key risks include [1] extensive regulatory and compliance hurdles specific to its international direct selling business model, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 7/14/2026
Natures Sunshine Products (NATR) stock has lost about 15% since 3/31/2026 because of the following key factors:
1. Mixed Fiscal Q1 2026 Financial Performance with Significant Operating Profit Decline.
Nature's Sunshine Products reported its fiscal first-quarter 2026 results on May 7, 2026. While diluted earnings per share (EPS) of $0.29 beat analyst estimates of $0.23, and net sales increased 9% year-over-year to $122.9 million, the company experienced a sharp decline in operating profit. Operating profit for the quarter fell by 86.3% year-over-year to $9.5 million. Additionally, cash from operating activities was negative $1.8 million, representing a decrease of approximately 170.8% compared to the prior year period. These mixed results, particularly the substantial drop in operating profit and negative operating cash flow, likely contributed to investor apprehension.
2. Anticipated Near-Term EBITDA Growth Reduction Due to Increased Investments.
Despite reiterating its full-year 2026 guidance for net sales between $500 million and $515 million and adjusted EBITDA between $50 million and $54 million, management indicated plans for heavier technology and growth investments during fiscal Q2 and Q3 2026 (ending June 30 and September 30, 2026, respectively). The company stated that these investments would "temporarily reduc[e] the double-digit EBITDA growth rate seen historically and in Q1 2026," suggesting a period of slower profit expansion. This outlook on near-term profitability likely dampened investor enthusiasm.
Show more
Natures Sunshine Products (NATR) stock has lost about 15% since 3/31/2026 because of the following key factors:
1. Mixed Fiscal Q1 2026 Financial Performance with Significant Operating Profit Decline.
Nature's Sunshine Products reported its fiscal first-quarter 2026 results on May 7, 2026. While diluted earnings per share (EPS) of $0.29 beat analyst estimates of $0.23, and net sales increased 9% year-over-year to $122.9 million, the company experienced a sharp decline in operating profit. Operating profit for the quarter fell by 86.3% year-over-year to $9.5 million. Additionally, cash from operating activities was negative $1.8 million, representing a decrease of approximately 170.8% compared to the prior year period. These mixed results, particularly the substantial drop in operating profit and negative operating cash flow, likely contributed to investor apprehension.
2. Anticipated Near-Term EBITDA Growth Reduction Due to Increased Investments.
Despite reiterating its full-year 2026 guidance for net sales between $500 million and $515 million and adjusted EBITDA between $50 million and $54 million, management indicated plans for heavier technology and growth investments during fiscal Q2 and Q3 2026 (ending June 30 and September 30, 2026, respectively). The company stated that these investments would "temporarily reduc[e] the double-digit EBITDA growth rate seen historically and in Q1 2026," suggesting a period of slower profit expansion. This outlook on near-term profitability likely dampened investor enthusiasm.
Show more
Updated on 7/14/2026
Natures Sunshine Products (NATR) stock has lost about 15% since 3/31/2026 because of the following key factors:
1. Mixed Fiscal Q1 2026 Financial Performance with Significant Operating Profit Decline.
Nature's Sunshine Products reported its fiscal first-quarter 2026 results on May 7, 2026. While diluted earnings per share (EPS) of $0.29 beat analyst estimates of $0.23, and net sales increased 9% year-over-year to $122.9 million, the company experienced a sharp decline in operating profit. Operating profit for the quarter fell by 86.3% year-over-year to $9.5 million. Additionally, cash from operating activities was negative $1.8 million, representing a decrease of approximately 170.8% compared to the prior year period. These mixed results, particularly the substantial drop in operating profit and negative operating cash flow, likely contributed to investor apprehension.
2. Anticipated Near-Term EBITDA Growth Reduction Due to Increased Investments.
Despite reiterating its full-year 2026 guidance for net sales between $500 million and $515 million and adjusted EBITDA between $50 million and $54 million, management indicated plans for heavier technology and growth investments during fiscal Q2 and Q3 2026 (ending June 30 and September 30, 2026, respectively). The company stated that these investments would "temporarily reduc[e] the double-digit EBITDA growth rate seen historically and in Q1 2026," suggesting a period of slower profit expansion. This outlook on near-term profitability likely dampened investor enthusiasm.
3. Cautious Stance on Geopolitical Impact on Demand and Costs.
During the Q1 fiscal 2026 earnings call, the company's management expressed a "cautious stance regarding the potential impact of the Iran conflict on both demand and cost." This acknowledgement of potential macroeconomic headwinds and geopolitical uncertainties could have contributed to investor caution, particularly given the company's international operations.
Show less
Natures Sunshine Products (NATR) stock has lost about 15% since 3/31/2026 because of the following key factors:
1. Mixed Fiscal Q1 2026 Financial Performance with Significant Operating Profit Decline.
Nature's Sunshine Products reported its fiscal first-quarter 2026 results on May 7, 2026. While diluted earnings per share (EPS) of $0.29 beat analyst estimates of $0.23, and net sales increased 9% year-over-year to $122.9 million, the company experienced a sharp decline in operating profit. Operating profit for the quarter fell by 86.3% year-over-year to $9.5 million. Additionally, cash from operating activities was negative $1.8 million, representing a decrease of approximately 170.8% compared to the prior year period. These mixed results, particularly the substantial drop in operating profit and negative operating cash flow, likely contributed to investor apprehension.
2. Anticipated Near-Term EBITDA Growth Reduction Due to Increased Investments.
Despite reiterating its full-year 2026 guidance for net sales between $500 million and $515 million and adjusted EBITDA between $50 million and $54 million, management indicated plans for heavier technology and growth investments during fiscal Q2 and Q3 2026 (ending June 30 and September 30, 2026, respectively). The company stated that these investments would "temporarily reduc[e] the double-digit EBITDA growth rate seen historically and in Q1 2026," suggesting a period of slower profit expansion. This outlook on near-term profitability likely dampened investor enthusiasm.
3. Cautious Stance on Geopolitical Impact on Demand and Costs.
During the Q1 fiscal 2026 earnings call, the company's management expressed a "cautious stance regarding the potential impact of the Iran conflict on both demand and cost." This acknowledgement of potential macroeconomic headwinds and geopolitical uncertainties could have contributed to investor caution, particularly given the company's international operations.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The -14.6% change in NATR stock from 3/31/2026 to 7/14/2026 was primarily driven by a -16.1% change in the company's P/E Multiple.| (LTM values as of) | 3312026 | 7142026 | Change |
|---|---|---|---|
| Stock Price ($) | 23.99 | 20.49 | -14.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 480 | 490 | 2.0% |
| Net Income Margin (%) | 4.1% | 4.1% | -0.1% |
| P/E Multiple | 21.5 | 18.0 | -16.1% |
| Shares Outstanding (Mil) | 17 | 18 | -0.1% |
| Cumulative Contribution | -14.6% |
Market Drivers
3/31/2026 to 7/14/2026| Return | Correlation | |
|---|---|---|
| NATR | -14.6% | |
| Market (SPY) | 15.6% | 22.6% |
| Sector (XLP) | 1.8% | 31.9% |
Fundamental Drivers
The -5.1% change in NATR stock from 12/31/2025 to 7/14/2026 was primarily driven by a -28.4% change in the company's P/E Multiple.| (LTM values as of) | 12312025 | 7142026 | Change |
|---|---|---|---|
| Stock Price ($) | 21.58 | 20.49 | -5.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 475 | 490 | 3.2% |
| Net Income Margin (%) | 3.2% | 4.1% | 27.7% |
| P/E Multiple | 25.2 | 18.0 | -28.4% |
| Shares Outstanding (Mil) | 18 | 18 | 0.7% |
| Cumulative Contribution | -5.1% |
Market Drivers
12/31/2025 to 7/14/2026| Return | Correlation | |
|---|---|---|
| NATR | -5.1% | |
| Market (SPY) | 10.6% | 15.6% |
| Sector (XLP) | 8.0% | 30.1% |
Fundamental Drivers
The 38.5% change in NATR stock from 6/30/2025 to 7/14/2026 was primarily driven by a 83.2% change in the company's Net Income Margin (%).| (LTM values as of) | 6302025 | 7142026 | Change |
|---|---|---|---|
| Stock Price ($) | 14.79 | 20.49 | 38.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 457 | 490 | 7.3% |
| Net Income Margin (%) | 2.2% | 4.1% | 83.2% |
| P/E Multiple | 27.0 | 18.0 | -33.2% |
| Shares Outstanding (Mil) | 18 | 18 | 5.5% |
| Cumulative Contribution | 38.5% |
Market Drivers
6/30/2025 to 7/14/2026| Return | Correlation | |
|---|---|---|
| NATR | 38.5% | |
| Market (SPY) | 22.7% | 7.5% |
| Sector (XLP) | 5.2% | 25.3% |
Fundamental Drivers
The 50.1% change in NATR stock from 6/30/2023 to 7/14/2026 was primarily driven by a 398.8% change in the company's Net Income Margin (%).| (LTM values as of) | 6302023 | 7142026 | Change |
|---|---|---|---|
| Stock Price ($) | 13.65 | 20.49 | 50.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 420 | 490 | 16.6% |
| Net Income Margin (%) | 0.8% | 4.1% | 398.8% |
| P/E Multiple | 76.1 | 18.0 | -76.3% |
| Shares Outstanding (Mil) | 19 | 18 | 8.8% |
| Cumulative Contribution | 50.1% |
Market Drivers
6/30/2023 to 7/14/2026| Return | Correlation | |
|---|---|---|
| NATR | 50.1% | |
| Market (SPY) | 75.6% | 17.3% |
| Sector (XLP) | 21.2% | 22.9% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| NATR Return | 31% | -55% | 108% | -15% | 47% | 0% | 52% |
| Peers Return | 20% | -43% | -5% | 22% | -2% | -14% | -34% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 10% | 100% |
Monthly Win Rates [3] | |||||||
| NATR Win Rate | 67% | 17% | 75% | 42% | 42% | 57% | |
| Peers Win Rate | 48% | 37% | 45% | 50% | 42% | 37% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 57% | |
Max Drawdowns [4] | |||||||
| NATR Max Drawdown | -33% | -58% | -24% | -44% | -25% | -29% | |
| Peers Max Drawdown | -34% | -55% | -50% | -46% | -48% | -45% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: USNA, HLF, NUS, LFVN, MTEX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/14/2026 (YTD)
How Low Can It Go
| Event | NATR | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -20.7% | -18.8% |
| % Gain to Breakeven | 26.1% | 23.1% |
| Time to Breakeven | 15 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -18.8% | -7.8% |
| % Gain to Breakeven | 23.2% | 8.5% |
| Time to Breakeven | 88 days | 18 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -56.8% | -24.5% |
| % Gain to Breakeven | 131.7% | 32.4% |
| Time to Breakeven | 490 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -40.3% | -33.7% |
| % Gain to Breakeven | 67.4% | 50.9% |
| Time to Breakeven | 138 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -18.7% | -19.2% |
| % Gain to Breakeven | 22.9% | 23.8% |
| Time to Breakeven | 81 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -45.4% | -3.7% |
| % Gain to Breakeven | 83.2% | 3.9% |
| Time to Breakeven | 1339 days | 6 days |
In The Past
Natures Sunshine Products's stock fell -20.7% during the 2025 US Tariff Shock. Such a loss loss requires a 26.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | NATR | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -20.7% | -18.8% |
| % Gain to Breakeven | 26.1% | 23.1% |
| Time to Breakeven | 15 days | 79 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -56.8% | -24.5% |
| % Gain to Breakeven | 131.7% | 32.4% |
| Time to Breakeven | 490 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -40.3% | -33.7% |
| % Gain to Breakeven | 67.4% | 50.9% |
| Time to Breakeven | 138 days | 140 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -45.4% | -3.7% |
| % Gain to Breakeven | 83.2% | 3.9% |
| Time to Breakeven | 1339 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -42.6% | -12.2% |
| % Gain to Breakeven | 74.2% | 13.9% |
| Time to Breakeven | 177 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -49.2% | -6.8% |
| % Gain to Breakeven | 97.0% | 7.3% |
| Time to Breakeven | 184 days | 15 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -37.5% | -17.9% |
| % Gain to Breakeven | 60.0% | 21.8% |
| Time to Breakeven | 679 days | 123 days |
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -33.3% | -15.4% |
| % Gain to Breakeven | 50.0% | 18.2% |
| Time to Breakeven | 300 days | 125 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -40.7% | -53.4% |
| % Gain to Breakeven | 68.7% | 114.4% |
| Time to Breakeven | 297 days | 1085 days |
In The Past
Natures Sunshine Products's stock fell -20.7% during the 2025 US Tariff Shock. Such a loss loss requires a 26.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Natures Sunshine Products (NATR)
Nature's Sunshine Products (NATR) is a natural health and wellness company specializing in the manufacturing and sale of nutritional supplements and personal care products. Founded in 1972, the company aims to support overall health through natural solutions.
The company offers a comprehensive range of products addressing various health concerns. Its nutritional offerings include general health support for areas like blood sugar, bone, cognitive function, joint health, mood, sleep, and energy, alongside specific products for immunity, cardiovascular, and digestive health. NATR also provides personal care items such as oils, lotions, herbal shampoos, skin treatments, and toothpaste, in addition to weight management solutions.
Nature's Sunshine Products distributes its goods globally under the Nature's Sunshine and Synergy WorldWide brands. It primarily reaches its customers through an independent sales force across international markets, including Asia, Europe, North America, and Latin America, serving individuals seeking natural health and wellness products.
AI Analysis | Feedback
Here are 1-3 brief analogies for Nature's Sunshine Products (NATR):
- Like Herbalife, but with a broader range of natural health and personal care products.
- An Amway focused specifically on natural wellness products.
AI Analysis | Feedback
- General Health Products: Nutritional supplements addressing various health concerns such as blood sugar support, bone health, cognitive function, and joint health.
- Immunity, Cardiovascular, and Digestive Products: Specialized nutritional supplements designed to support immune system function, heart health, and digestive wellness.
- Personal Care Products: Items for external use, including oils, lotions, aloe vera gels, herbal shampoos, and skin cleansers.
- Weight Management Products: Nutritional supplements and programs developed to assist with healthy weight loss or maintenance.
AI Analysis | Feedback
Nature's Sunshine Products (NATR) sells its products primarily to individuals through a sales force of independent consultants. The company does not have major corporate customers in the traditional B2B sense. Instead, its products are targeted at and consumed by a broad range of individual consumers. Based on its product offerings, the major categories of customers that it serves include:
- Health-Conscious Individuals Seeking General Wellness: This category includes consumers who are proactive about maintaining overall health and well-being. They purchase products for general health support such as immunity, cardiovascular, digestive health, bone health, cellular health, cognitive function, mood, sleep, and vision.
- Individuals with Specific Health Goals or Concerns: This group comprises customers who are looking for solutions related to particular health objectives, such as weight management, sports performance and energy, or sexual health.
- Consumers Prioritizing Natural Personal Care: This segment consists of individuals interested in using natural and herbal ingredients for their personal care routines, including products like aloe vera gels, herbal shampoos, skin treatments, toothpaste, and skin cleansers.
AI Analysis | Feedback
null
AI Analysis | Feedback
Kenneth Romanzi
Chief Executive Officer
Mr. Romanzi brings over 40 years of experience in leadership positions with consumer-packaged goods (CPG) companies, and was appointed CEO of Nature's Sunshine Products in October 2025. He served as President, CEO, and a Board Member of B&G Foods, Inc., a public company, where he led a strategic transformation, expanding revenue and improving profitability. Earlier in his career, he held C-Suite and leadership roles at prominent CPG companies such as Nabisco; The Ultimate Juice Company, including the Naked Juice brand which was subsequently acquired by PepsiCo, Inc.; Hasbro, Inc.; and Ocean Spray Cranberries, Inc. Most recently, Mr. Romanzi served as an Operating Partner for Ronin Equity Partners from May 2021 to October 2025 and a Strategic Advisor for Astara Capital Partners from September 2022 to October 2025, both private equity firms.
Shane Jones
Executive Vice President, Chief Financial Officer
Mr. Jones was appointed Chief Financial Officer of Nature's Sunshine in December 2022, bringing over 25 years of finance experience. He previously served as Chief Financial Officer at FullSpeed Automotive (since January 2022), West Marine (January 2020 - August 2021), 1-800 Contacts (February 2018 - February 2019), and Backcountry.com (December 2015 - February 2018). Prior to 2015, Mr. Jones held senior leadership roles at various retail and direct-to-consumer brands, including Amazon.com, Limited Brands, and Yum! Brands. He notably served as CFO for three different private equity-owned, direct-to-consumer companies.
Nathan G. Brower
Executive Vice President, General Counsel and Secretary
Mr. Brower was appointed Executive Vice President, General Counsel, and Secretary in December 2017. He joined Nature's Sunshine in May 2015, initially serving as Senior Director, Legal Counsel. Before joining Nature's Sunshine, Mr. Brower was Associate General Counsel at LifeVantage, Inc., a publicly-traded network marketing company, from July 2011 until May 2015. He also worked as a securities and corporate attorney in private practice at a large multinational law firm.
Kevin Fuller
Global Chief Marketing Officer
Mr. Fuller was named Global Chief Marketing Officer of Nature's Sunshine in September 2024. He brings nearly two decades of global marketing experience to the company, with a deep understanding of the supplement industry. Prior to Nature's Sunshine, he served as President & Chief Marketing Officer at Helo Health and CEO & Chief Marketing Officer at MacuVu Macular Health. Earlier in his career, he held senior leadership roles at NuSkin (Senior Vice President of Global Product & Brand), Pharmanex, and USANA.
Kevin Herbert
Executive Vice President, President North America
Mr. Herbert joined Nature's Sunshine as Executive Vice President, President North America in June 2023. He brings over 25 years of global experience in leading transformation and growth, having served in numerous executive and senior leadership positions for companies such as Samsung, Borden, Hain Celestial, White Wave Foods, and Procter & Gamble. Before joining Nature's Sunshine, Kevin led Crossmark's Natural Specialty Channel, where he achieved significant year-over-year growth.
AI Analysis | Feedback
Nature's Sunshine Products (NATR) faces several key risks inherent to its business model and global operations.
Key Risks to Nature's Sunshine Products (NATR)
- Regulatory and Compliance Risks: The company operates in a highly regulated environment across multiple international markets, facing laws and administrative actions related to product formulation, advertising, and sales. Delays in product registration, potential product liability exposure, and compliance with anti-bribery regulations (like the FCPA) are significant concerns. The decentralized nature of its sales force, comprising independent consultants, increases the risk of improper product claims, which could lead to stricter regulatory scrutiny and legal issues. There have been past instances involving alleged violations of the Foreign Corrupt Practices Act in a foreign subsidiary.
- Dependence on Independent Consultants and Challenges of the Multi-Level Marketing (MLM) Model: A substantial portion of Nature's Sunshine's revenue, particularly in certain markets, is highly dependent on its network of independent consultants and their sales efforts. The loss or inactivity of key consultants or challenges in recruiting and retaining a motivated sales force could materially impact financial results. The multi-level marketing business model itself carries inherent risks, including potential accusations of fraud, making false health claims, or an excessive focus on recruitment over product sales, which can lead to high turnover rates and reputational damage.
- International Exposure and Related Economic/Geopolitical Volatility: With approximately 72.2% of its net sales in 2025 generated from markets outside the United States, Nature's Sunshine is highly exposed to currency exchange fluctuations and geopolitical events. A stronger U.S. dollar can negatively impact reported earnings. Evolving U.S. trade policies, including tariffs and other restrictions, also introduce uncertainty and potential volatility, which could increase material costs or reduce demand for its products globally.
AI Analysis | Feedback
The clear emerging threat to Nature's Sunshine Products is the accelerating shift in consumer purchasing habits towards digitally-native channels, specifically the proliferation of direct-to-consumer (D2C) brands, social commerce, and influencer marketing in the health and wellness sector. These models offer consumers highly convenient, often personalized, and less interpersonally demanding ways to discover and acquire products, thereby directly challenging the efficacy and appeal of Nature's Sunshine's traditional independent consultant-based direct selling model and potentially eroding its customer base and recruitment pipeline.
AI Analysis | Feedback
Nature's Sunshine Products (NATR) operates within the global nutritional supplements, personal care products, and weight management markets. The addressable market sizes for their main products and services vary by region and product category.
Nutritional Supplements
- The global nutritional supplements market was estimated at USD 517.09 billion in 2025 and is projected to reach USD 862.51 billion by 2033.
- In North America, the nutritional supplements market generated approximately USD 144.687 billion in 2025 and is expected to reach USD 211.43 billion by 2033.
Personal Care Products
- The global beauty and personal care products market size was valued at USD 557.88 billion in 2024 and is expected to reach USD 818.42 billion in 2033.
- For North America, the beauty and personal care products market is estimated at USD 129.45 billion in 2025 and is expected to reach USD 157.12 billion by 2030.
Weight Management Products
- The global weight management market was valued at USD 38.60 billion in 2024 and is projected to reach USD 79.59 billion by 2035.
- The North America weight management products market was valued at approximately USD 7.74 billion in 2024 and is expected to reach around USD 11.12 billion by 2033.
AI Analysis | Feedback
Nature's Sunshine Products (NATR) anticipates several key drivers to fuel its revenue growth over the next 2-3 years:
- Accelerated Digital Transformation and E-commerce Expansion: The company expects continued robust growth from its digital platforms and subscription programs, particularly in North America and Asia. Management plans to invest in technology infrastructure and digital marketing to deepen channel penetration and drive recurring revenue, building on significant increases in North America digital sales and digital subscriptions observed in 2025.
- Geographic Expansion and Deeper Market Penetration: Nature's Sunshine aims to grow in existing regions, such as North America, Europe, and Asia-Pacific, while also strategically exploring new high-value markets. The company plans to expand its penetration within current markets, with Europe, for instance, demonstrating strong sales growth.
- Product Innovation and New Product Launches: The acceleration of product innovation and the introduction of new products are expected to be significant contributors to future revenue. This strategy also helps in differentiating products by channel and minimizing potential conflict between sales channels. The company is looking to expand its portfolio with plant-based and ESG-aligned offerings.
- Enhanced Customer Acquisition: Driving further customer acquisition is a stated objective, with a focus on leveraging digital channels and marketing campaigns, including platforms like TikTok, which have proven effective in attracting new customers. The company continues to rely on its sales force of independent consultants while also navigating the growth of direct-to-consumer sales channels like Amazon.
- Strategic Investments in Growth Initiatives: Nature's Sunshine plans measured investments in improving its technology infrastructure, fostering customer acquisition, advancing geographic expansion, enhancing market penetration, and accelerating product innovation. These investments are integral to supporting the company's broader vision for accelerated top-line growth.
AI Analysis | Feedback
Share Repurchases
- Nature's Sunshine Products repurchased 1,260,000 shares for $16.3 million during the year ended December 31, 2025.
- As of December 31, 2025, approximately $17.4 million remained authorized under the company's share repurchase program.
- In 2024, the company repurchased 540,000 shares at a cost of $8.9 million.
- An additional $25.0 million was authorized for share repurchases on May 6, 2025. This was in addition to a $15.0 million program announced in March 2021 and an additional $30.0 million authorized in March 2022.
Share Issuance
- In June 2025, a secondary public offering of up to 2,854,607 shares of common stock was announced, to be sold by Fosun Pharma USA, Inc. Nature's Sunshine Products was not selling any shares and would not receive any proceeds from this offering.
- The CEO, Kenneth G. Romanzi, received a grant of 29,928 common-share-equivalent restricted stock units (RSUs) in March 2026, granted under an employment agreement dated October 10, 2025.
Inbound Investments
- No significant inbound investments by third-parties (e.g., a strategic partner or a private equity firm) in Nature's Sunshine Products were prominently disclosed in the provided timeframe.
Outbound Investments
- No significant strategic outbound investments made by Nature's Sunshine Products in other companies were prominently disclosed in the provided timeframe.
Capital Expenditures
- Capital expenditures totaled $6.5 million for the twelve months ended December 31, 2025.
- Capital expenditures were $11.0 million in 2024.
- Capital expenditures were $10.5 million in 2023 and $7.6 million in 2022.
- The company's capital allocation structure supports continuing digital transformation and other strategic initiatives.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Natures Sunshine Products Earnings Notes | 12/16/2025 | |
| Can Natures Sunshine Products Stock Hold Up When Markets Turn? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 9.22 |
| Mkt Cap | 0.3 |
| Rev LTM | 708 |
| Op Inc LTM | 39 |
| FCF LTM | 13 |
| FCF 3Y Avg | 29 |
| CFO LTM | 24 |
| CFO 3Y Avg | 40 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -1.9% |
| Rev Chg 3Y Avg | -1.8% |
| Rev Chg Q | -3.0% |
| QoQ Delta Rev Chg LTM | -0.7% |
| Op Inc Chg LTM | 21.8% |
| Op Inc Chg 3Y Avg | 1.0% |
| Op Mgn LTM | 5.5% |
| Op Mgn 3Y Avg | 4.6% |
| QoQ Delta Op Mgn LTM | -0.0% |
| CFO/Rev LTM | 4.3% |
| CFO/Rev 3Y Avg | 6.0% |
| FCF/Rev LTM | 2.4% |
| FCF/Rev 3Y Avg | 4.2% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| General health | 192 | 184 | 174 | 159 | 163 |
| Digestive | 124 | 112 | 104 | 96 | 107 |
| Cardiovascular | 82 | 82 | 84 | 81 | 78 |
| Immune | 41 | 39 | 32 | 30 | 33 |
| Personal care | 23 | 18 | 18 | 22 | 33 |
| Weight management | 18 | 21 | 33 | 35 | 31 |
| Total | 480 | 454 | 445 | 422 | 444 |
| $ Mil | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|
| NSPAmericas | 75 | 76 | |||
| Synergy Worldwide | 35 | 44 | 38 | 36 | 10 |
| NSP Russia, Central and Eastern Europe | 9 | 18 | 23 | 22 | |
| China and New Markets | 2 | 2 | |||
| Adjustment | -108 | -120 | -121 | ||
| NSP Americas, Asia Pacific and Europe | 84 | 83 | |||
| Selling, general and administrative | -107 | ||||
| Nature’s Sunshine Products | 11 | ||||
| Total | 14 | 19 | 24 | 34 | 20 |
| $ Mil | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|
| NSPAmericas | 141 | 129 | |||
| Synergy Worldwide | 38 | 41 | 40 | 49 | 42 |
| China and New Markets | 16 | 20 | |||
| NSP Russia, Central and Eastern Europe | 5 | 7 | 11 | 9 | |
| NSP Americas, Asia Pacific and Europe | 148 | 136 | |||
| Nature’s Sunshine Products | 134 | ||||
| Total | 201 | 197 | 200 | 194 | 176 |
Price Behavior
Price Behavior
| Market Price | $20.49 | |
| Market Cap ($ Bil) | 0.4 | |
| First Trading Date | 02/23/2007 | |
| Distance from 52W High | -26.3% | |
| 50 Days | 200 Days | |
| DMA Price | $21.55 | $21.90 |
| DMA Trend | up | down |
| Distance from DMA | -4.9% | -6.4% |
| 3M | 1YR | |
| Volatility | 33.4% | 48.0% |
| Downside Capture | 89.45 | 26.28 |
| Upside Capture | -52.45 | 50.84 |
| Correlation (SPY) | 10.2% | 8.6% |
NATR Betas & Captures as of 6/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.25 | -0.03 | 0.50 | 0.39 | 0.29 | 0.52 |
| Up Beta | 0.39 | 1.46 | 1.31 | 1.01 | 0.37 | 0.41 |
| Down Beta | -0.21 | -0.69 | -0.65 | 0.32 | -0.04 | 0.53 |
| Up Capture | -29% | -83% | 4% | 11% | 49% | 29% |
| Bmk +ve Days | 11 | 24 | 40 | 67 | 140 | 429 |
| Stock +ve Days | 13 | 18 | 29 | 63 | 125 | 358 |
| Down Capture | -56% | 51% | 84% | 28% | 20% | 78% |
| Bmk -ve Days | 10 | 17 | 23 | 58 | 112 | 321 |
| Stock -ve Days | 7 | 22 | 33 | 61 | 124 | 378 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NATR | |
|---|---|---|---|---|
| NATR | 31.3% | 47.9% | 0.70 | - |
| Sector ETF (XLP) | 5.4% | 13.5% | 0.14 | 25.5% |
| Equity (SPY) | 21.7% | 12.6% | 1.28 | 8.2% |
| Gold (GLD) | 20.5% | 27.9% | 0.65 | 1.8% |
| Commodities (DBC) | 27.3% | 18.9% | 1.14 | -14.7% |
| Real Estate (VNQ) | 13.0% | 13.9% | 0.64 | 25.1% |
| Bitcoin (BTCUSD) | -47.0% | 42.7% | -1.37 | 0.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NATR | |
|---|---|---|---|---|
| NATR | 1.6% | 42.8% | 0.16 | - |
| Sector ETF (XLP) | 6.3% | 13.5% | 0.25 | 24.7% |
| Equity (SPY) | 13.1% | 17.1% | 0.59 | 24.7% |
| Gold (GLD) | 17.2% | 18.4% | 0.76 | 0.4% |
| Commodities (DBC) | 8.6% | 19.5% | 0.33 | -0.0% |
| Real Estate (VNQ) | 2.7% | 18.9% | 0.04 | 25.7% |
| Bitcoin (BTCUSD) | 12.8% | 53.4% | 0.42 | 16.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NATR | |
|---|---|---|---|---|
| NATR | 7.8% | 48.7% | 0.34 | - |
| Sector ETF (XLP) | 7.0% | 14.8% | 0.34 | 26.2% |
| Equity (SPY) | 15.4% | 17.9% | 0.73 | 32.5% |
| Gold (GLD) | 11.2% | 16.1% | 0.57 | 1.5% |
| Commodities (DBC) | 6.3% | 18.0% | 0.27 | 8.6% |
| Real Estate (VNQ) | 5.0% | 20.7% | 0.21 | 28.7% |
| Bitcoin (BTCUSD) | 57.3% | 66.2% | 0.97 | 10.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 6/10/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/7/2026 | -1.3% | -9.2% | -19.5% |
| 3/10/2026 | -1.3% | -4.3% | 7.9% |
| 11/6/2025 | 30.5% | 51.1% | 56.7% |
| 7/31/2025 | 12.8% | 9.6% | 20.3% |
| 11/7/2024 | 7.5% | 15.4% | 15.8% |
| 8/9/2024 | -6.7% | 3.8% | 3.6% |
| 5/8/2024 | -0.9% | 0.0% | -4.6% |
| 3/12/2024 | 15.6% | 13.5% | 12.4% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 9 | 12 | 14 |
| # Negative | 11 | 8 | 6 |
| Median Positive | 7.5% | 3.6% | 8.4% |
| Median Negative | -1.3% | -4.3% | -6.8% |
| Max Positive | 30.5% | 51.1% | 56.7% |
| Max Negative | -6.8% | -9.2% | -19.5% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/7/2026 | -1.3% | -9.2% | -19.5% |
| 3/10/2026 | -1.3% | -4.3% | 7.9% |
| 11/6/2025 | 30.5% | 51.1% | 56.7% |
| 7/31/2025 | 12.8% | 9.6% | 20.3% |
| 11/7/2024 | 7.5% | 15.4% | 15.8% |
| 8/9/2024 | -6.7% | 3.8% | 3.6% |
| 5/8/2024 | -0.9% | 0.0% | -4.6% |
| 3/12/2024 | 15.6% | 13.5% | 12.4% |
| 11/7/2023 | -4.3% | -4.3% | -7.3% |
| 8/10/2023 | 5.5% | 3.4% | 7.9% |
| 5/9/2023 | -1.0% | -0.8% | 12.2% |
| 3/16/2023 | 1.3% | 0.2% | 1.1% |
| 8/10/2022 | -0.8% | -3.2% | -10.3% |
| 5/6/2022 | -6.8% | -7.3% | -6.2% |
| 3/9/2022 | 4.1% | 3.3% | 4.4% |
| 8/6/2021 | -2.3% | -4.0% | 1.9% |
| 5/7/2021 | -1.3% | -6.0% | -2.0% |
| 3/11/2021 | -2.4% | 2.0% | 6.6% |
| 11/9/2020 | 10.4% | 20.6% | 31.7% |
| 8/7/2020 | 1.3% | 2.3% | 8.9% |
| SUMMARY STATS | |||
| # Positive | 9 | 12 | 14 |
| # Negative | 11 | 8 | 6 |
| Median Positive | 7.5% | 3.6% | 8.4% |
| Median Negative | -1.3% | -4.3% | -6.8% |
| Max Positive | 30.5% | 51.1% | 56.7% |
| Max Negative | -6.8% | -9.2% | -19.5% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 03/10/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 07/31/2025 | 10-Q |
| 03/31/2025 | 05/06/2025 | 10-Q |
| 12/31/2024 | 03/11/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 03/12/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 03/16/2023 | 10-K |
| 09/30/2022 | 11/03/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 03/10/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 07/31/2025 | 10-Q |
| 03/31/2025 | 05/06/2025 | 10-Q |
| 12/31/2024 | 03/11/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 03/12/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 03/16/2023 | 10-K |
| 09/30/2022 | 11/03/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
| 03/31/2022 | 05/05/2022 | 10-Q |
| 12/31/2021 | 03/08/2022 | 10-K |
| 09/30/2021 | 11/04/2021 | 10-Q |
| 06/30/2021 | 08/05/2021 | 10-Q |
| 03/31/2021 | 05/06/2021 | 10-Q |
| 12/31/2020 | 03/10/2021 | 10-K |
| 09/30/2020 | 11/09/2020 | 10-Q |
| 06/30/2020 | 08/06/2020 | 10-Q |
| 03/31/2020 | 05/11/2020 | 10-Q |
| 12/31/2019 | 03/11/2020 | 10-K |
| 09/30/2019 | 11/07/2019 | 10-Q |
| 06/30/2019 | 08/09/2019 | 10-Q |
Recent Forward Guidance
Updated 7/12/2026Latest: Q1 2026 Earnings Reported 5/7/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 500.00 Mil | 507.50 Mil | 515.00 Mil | 0 | Affirmed | Guidance: 507.50 Mil for 2026 | |
| 2026 Adjusted EBITDA | 50.00 Mil | 52.00 Mil | 54.00 Mil | 0 | Affirmed | Guidance: 52.00 Mil for 2026 | |
Prior: Q4 2025 Earnings Reported 3/10/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Net Sales | 500.00 Mil | 507.50 Mil | 515.00 Mil | 6.2% | Higher New | Guidance: 478.00 Mil for 2025 | |
| 2026 Adjusted EBITDA | 50.00 Mil | 52.00 Mil | 54.00 Mil | 8.3% | Higher New | Guidance: 48.00 Mil for 2025 | |
Q3 2025 Earnings Reported 11/6/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2025 Net Sales | 476.00 Mil | 478.00 Mil | 480.00 Mil | 2.2% | Raised | Guidance: 467.50 Mil for 2025 | |
| 2025 Adjusted EBITDA | 47.00 Mil | 48.00 Mil | 49.00 Mil | 11.6% | Raised | Guidance: 43.00 Mil for 2025 | |
Insider Activity
Updated 6/29/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Herbert, Kevin R | EVP & President, North America | Direct | Sell | 6152026 | 20.68 | 2,000 | 41,364 | 1,010,645 | Form |
| 2 | Yates, Bryant J | EVP & President, Europe | Direct | Sell | 6112026 | 19.90 | 11,968 | 238,163 | 1,541,175 | Form |
| 3 | Norman, Daniel C | EVP & President, Asia | Direct | Sell | 6032026 | 20.64 | 9,713 | 200,476 | 975,777 | Form |
| 4 | Brower, Nathan G | EVP, General Counsel | Direct | Sell | 5222026 | 21.84 | 12,015 | 262,408 | 948,686 | Form |
| 5 | Yates, Bryant J | EVP & President, Europe | Direct | Sell | 3172026 | 24.35 | 19,516 | 475,215 | 2,073,500 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Herbert, Kevin R | EVP & President, North America | Direct | Sell | 6152026 | 20.68 | 2,000 | 41,364 | 1,010,645 | Form |
| 2 | Yates, Bryant J | EVP & President, Europe | Direct | Sell | 6112026 | 19.90 | 11,968 | 238,163 | 1,541,175 | Form |
| 3 | Norman, Daniel C | EVP & President, Asia | Direct | Sell | 6032026 | 20.64 | 9,713 | 200,476 | 975,777 | Form |
| 4 | Brower, Nathan G | EVP, General Counsel | Direct | Sell | 5222026 | 21.84 | 12,015 | 262,408 | 948,686 | Form |
| 5 | Yates, Bryant J | EVP & President, Europe | Direct | Sell | 3172026 | 24.35 | 19,516 | 475,215 | 2,073,500 | Form |
| 6 | Norman, Daniel C | EVP & President, Asia | Direct | Sell | 3172026 | 24.52 | 15,383 | 377,191 | 1,365,592 | Form |
| 7 | Lanoy, Jonathan David | SVP, Chief Accounting Officer | Direct | Sell | 3162026 | 24.70 | 4,000 | 98,800 | 1,146,204 | Form |
| 8 | Yates, Bryant J | EVP & President, Europe | Direct | Sell | 12162025 | 22.29 | 1,700 | 37,893 | 2,197,883 | Form |
| 9 | Lanoy, Jonathan David | SVP, Chief Accounting Officer | Direct | Sell | 11192025 | 20.45 | 5,000 | 102,250 | 945,465 | Form |
| 10 | Norman, Daniel C | EVP & President, Asia | Direct | Sell | 11192025 | 20.46 | 8,884 | 181,767 | 1,363,373 | Form |
| 11 | Brower, Nathan G | EVP, General Counsel | Direct | Sell | 11182025 | 20.81 | 3,800 | 79,078 | 972,555 | Form |
| 12 | Yates, Bryant J | EVP & President, Europe | Direct | Sell | 9042025 | 16.71 | 4,672 | 78,069 | 1,629,192 | Form |
| 13 | Yates, Bryant J | EVP & President, Europe | Direct | Sell | 9042025 | 16.77 | 5,000 | 83,850 | 1,713,391 | Form |
| 14 | Lanoy, Jonathan David | SVP, Chief Accounting Officer | Direct | Sell | 8152025 | 16.51 | 5,000 | 82,550 | 826,342 | Form |
| 15 | Brower, Nathan G | EVP, General Counsel | Direct | Sell | 8152025 | 16.54 | 9,996 | 165,334 | 798,502 | Form |
| 16 | Shanghai, Fosun Pharmaceutical (group) Co, Ltd | by Fosun Pharma USA Inc. | Sell | 6272025 | 11.46 | 2,854,607 | Form |
Natures Sunshine Products — Investor Video Playlist
Products & Services
We Go to the Source
Products & Services
Farmers Market Finds… or Just One Scoop of Power Greens? 🥬✨
Products & Services
Brain Edge = Instant Productivity? 👀🧠✨
Products & Services
Strawberry Rose Glow Mocktail ✨🍓 (Collagen-Infused!)
Products & Services
Tei-Fu Lotion = Instant Relief 💆♀️✨
Products & Services
Introducing NEW! Chlorophyll Stick Packs from Nature's Sunshine
Industry Resources
| Consumer Staples Resources |
| FoodNavigator |
| Consumer Goods Technology (CGT) |
| Beverage Digest |
| Packaged Foods & Meats Resources |
| USDA Data |
| Food Processing |
| Meat+Poultry |
| Just Food |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 7/14/2026